S&P Futures
3,899.75 -4.00 (-0.10%) Dow Futures
31,413.00 -8.00 (-0.03%) Nasdaq Futures
12,023.00 -17.50 (-0.15%) Russell 2000 Futures
1,769.70 -0.10 (-0.01%) Crude Oil
110.91 +1.34 (+1.22%) Gold
1,827.60 +2.80 (+0.15%)
RedHill Biopharma Ltd. (RDHL)
After hours:
Chart Events
Performance Outlook
| Previous Close | 0.8200 |
| Open | 0.8545 |
| Bid | 0.9800 x 900 |
| Ask | 1.0000 x 29200 |
| Day's Range | 0.8300 - 1.0270 |
| 52 Week Range | 0.6200 - 11.1800 |
| Volume | |
| Avg. Volume | 1,914,048 |
| Market Cap | 53.45M |
| Beta (5Y Monthly) | 1.79 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
- American City Business Journals
Raleigh drugmaker slashes workforce as biotech downturn deepens
The drugmaker is cutting one-third of its U.S. commercial workforce as part of a plan to save $50 million. The move comes as the biotech industry sees cuts across the board as the highs of the pandemic fade away.
- Benzinga
RedHill Biopharma Shares Trading Higher On Improved Q1 Profitability
View more earnings on RDHLSee more from BenzingaThe Daily Biotech Pulse: F-Star Therapeutics Buyout, Orphan Drug Tag For VBI's Brain Cancer Vaccine, Xenon's Epilepsy Candidate Shows PromiseDon't miss real-time alerts on your stocks - join Benzinga Pro for free! Try the tool that will help you invest smarter, faster, and better.© 2022 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
- American City Business Journals
Raleigh drugmaker pursuing Covid treatment raising $15M to fund acquisitions
Additionally, the company agreed to issue unregistered private warrants to the investor to purchase up to more than 13 million shares at $1.48 a share in a concurrent private placement, according to a filing with the U.S. Securities and Exchange Commission. RedHill's stock fell more than 30 percent Monday after the company disclosed the offering prior to markets opening. The offering follows the company signing a licensing deal with the South Korean corporation Kubo Co. Ltd for the exclusive rights to commercialize RedHill's investigational Covid-19 treatment called opaganib.
